Octaplasmalg (Ab) (Human Plasma Protein)

Human Plasma Protein contains a balanced mix of clotting factors, albumin, and immunoglobulins. When infused, it expands plasma volume and directly replaces missing or reduced clotting proteins, thereby enhancing both the intrinsic and extrinsic pathways of the coagulation cascade and promoting effective blood clot formation.

The dosage of Octaplasmalg (Ab) is individualized and determined by the prescribing clinician based on the patient’s specific clinical condition, weight, coagulation profile, and the extent of plasma protein deficiency. Healthcare professionals calculate the appropriate volume to achieve the desired therapeutic effect.

Safety data for Octaplasmalg (Ab) in pregnancy and lactation are limited. It should only be used when clearly needed and after a risk‑benefit assessment by the treating physician. The potential benefits of correcting a serious coagulation disorder must outweigh any theoretical risks to the fetus or infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and necessary import documentation.

Octaplasmalg (Ab) offers a standardized, pathogen‑reduced plasma protein preparation that provides a broad spectrum of clotting factors, similar to other plasma‑derived concentrates. Compared with single‑factor concentrates, it can address multiple deficiencies simultaneously, but clinicians may choose specific factor products when a single deficiency is identified.

Octaplasmalg (Ab) must be stored at 2‑8 °C, protected from light, and kept in its original container. It should not be frozen or shaken. Prior to administration, inspect the product for any discoloration or particulate matter and allow it to reach room temperature if required by the infusion protocol.

Octaplasmalg (Ab) is administered intravenously under the supervision of qualified healthcare personnel. The infusion rate is typically controlled to minimize adverse reactions, and patients are monitored for vital signs and any signs of hypersensitivity throughout the administration.

Serious risks include anaphylactic reactions, transfusion‑related acute lung injury (TRALI), acute hemolytic transfusion reactions, severe thrombosis, and the theoretical risk of viral transmission despite rigorous pathogen reduction processes. Prompt recognition and management of these events are essential.

Octaplasmalg (Ab) is contraindicated in individuals with a known hypersensitivity to human plasma proteins or any of the product’s excipients. It should also be avoided in patients with uncontrolled volume overload, severe cardiac failure, or those who have experienced prior severe transfusion reactions.